论文部分内容阅读
目的探讨缩宫素配伍欣母沛治疗及预防宫缩乏力导致产后出血的临床效果。方法选择2008年1月~2010年12月合并有羊水过多、多胎妊娠、巨大胎儿、宫缩乏力,前置胎盘等产后出血高危因素的孕妇90例,随机分为对照组和治疗组,对照组采用胎儿娩出后常规静脉滴注缩宫素,治疗组采用常规静脉滴注缩宫素基础上宫体注射欣母沛,比较两组的治疗效果及不良反应。结果治疗组产后出血发生率12.8%,明显低于对照组的40.2%,其平均出血量306±68ml,明显低于对照组的440±92ml,但不良反应发生率为87.3%,明显高于对照组的29.4%,差异有统计学意义(P<0.05)。发生不良反应的产妇均可自行恢复,无严重并发症发生。结论缩宫素配伍欣母沛治疗及预防宫缩乏力性产后出血安全可靠,值得推广。
Objective To investigate the clinical effect of oxytocin combined with Xinmaopen on the prevention and treatment of uterine atony caused by postpartum hemorrhage. Methods From January 2008 to December 2010, 90 pregnant women with polyhydramnios, multiple pregnancies, huge fetuses, uterine atony, placenta previa and other high risk factors for postpartum hemorrhage were randomly divided into control group and treatment group, control group In the group, conventional oxytocin was used after the fetus was delivered. The treatment group was given routine intravenous oxytocin injection of Yan-Pei on the basis of oxytocin, and the therapeutic effects and adverse reactions of the two groups were compared. Results The incidence of postpartum hemorrhage in treatment group was 12.8%, which was significantly lower than that in control group (40.2%). The average amount of bleeding was 306 ± 68ml, which was significantly lower than 440 ± 92ml in control group, but the incidence of adverse reactions was 87.3% Group 29.4%, the difference was statistically significant (P <0.05). Maternal adverse reactions can be self-healing, no serious complications. Conclusion oxytocin compatibility Xinmaitai treatment and prevention of uterine atony postpartum hemorrhage safe and reliable, it is worth promoting.